
Bruno Annibale

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1974189/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy, 2019, 51, 365-388.	1.0	587
2	Meticulous Prevention of Hypoglycemia Normalizes the Glycemic Thresholds and Magnitude of Most of Neuroendocrine Responses to, Symptoms of, and Cognitive Function During Hypoglycemia in Intensively Treated Patients With Short-Term IDDM. Diabetes, 1993, 42, 1683-1689.	0.3	380
3	Thyroxine in Goiter,Helicobacter pyloriInfection, and Chronic Gastritis. New England Journal of Medicine, 2006, 354, 1787-1795.	13.9	284
4	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations. Neuroendocrinology, 2009, 90, 167-183.	1.2	246
5	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs. Neuroendocrinology, 2009, 90, 220-226.	1.2	232
6	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology, 2009, 90, 194-202.	1.2	226
7	Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia, 1994, 37, 1265-1276.	2.9	202
8	Pernicious anemia: New insights from a gastroenterological point of view. World Journal of Gastroenterology, 2009, 15, 5121.	1.4	193
9	Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans. Diabetologia, 1994, 37, 797-807.	2.9	181
10	Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. American Journal of Medicine, 2001, 111, 439-445.	0.6	180
11	Reversal of Iron Deficiency Anemia after <i>Helicobacter pylori</i> Eradication in Patients with Asymptomatic Gastritis. Annals of Internal Medicine, 1999, 131, 668.	2.0	176
12	A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. Endoscopy, 2016, 48, 723-730.	1.0	170
13	Systematic review: gastric cancer incidence in pernicious anaemia. Alimentary Pharmacology and Therapeutics, 2013, 37, 375-382.	1.9	164
14	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with ¹¹¹ In-Pentetreotide. Neuroendocrinology, 2009, 90, 184-189.	1.2	162
15	Concomitant alterations in intragastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia. Gut, 2003, 52, 496-501.	6.1	152
16	Atrophic Body Gastritis in Patients With Autoimmune Thyroid Disease. Archives of Internal Medicine, 1999, 159, 1726.	4.3	147
17	Effect of chronic hypergastrinemia on human enterochromaffin-like cells: Insights from patients with sporadic gastrinomas. Gastroenterology, 2002, 123, 68-85.	0.6	146
18	Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterology Journal, 2014, 2, 413-442.	1.6	141

#	Article	IF	CITATIONS
19	A Prospective Study of Gastric Carcinoids and Enterochromaffin-Like Cell Changes in Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Identification of Risk Factors. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1582-1591.	1.8	137
20	Reassessment of Intrinsic Factor and Parietal Cell Autoantibodies in Atrophic Gastritis With Respect to Cobalamin Deficiency. American Journal of Gastroenterology, 2009, 104, 2071-2079.	0.2	130
21	Systematic review: distribution of advanced neoplasia according to polyp size at screening colonoscopy. Alimentary Pharmacology and Therapeutics, 2010, 31, 210-217.	1.9	130
22	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation. Neuroendocrinology, 2009, 90, 227-233.	1.2	128
23	Reversal of Long-Standing Iron Deficiency Anaemia after Eradication of <i>Helicobacter pylori</i> Infection. Scandinavian Journal of Gastroenterology, 1997, 32, 617-622.	0.6	127
24	Efficacy of gluten-free diet alone on recovery from iron deficiency anemia in adult celiac patients. American Journal of Gastroenterology, 2001, 96, 132-137.	0.2	124
25	Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Alimentary Pharmacology and Therapeutics, 2000, 14, 625-634.	1.9	114
26	Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal. World Journal of Gastroenterology, 2012, 18, 1279.	1.4	111
27	Proton pump inhibitor therapy and potential long-term harm. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 3-8.	1.2	108
28	Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. European Journal of Gastroenterology and Hepatology, 2001, 13, 1449-1456.	0.8	106
29	Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Digestive and Liver Disease, 2015, 47, 903-912.	0.4	106
30	High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic and macrocytic anemia A prospective screening study. American Journal of Gastroenterology, 1999, 94, 766-772.	0.2	104
31	Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. Journal of Endocrinological Investigation, 2004, 27, 6-11.	1.8	104
32	Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate. Neuroendocrinology, 2012, 95, 207-213.	1.2	104
33	Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes, 1993, 42, 1683-1689.	0.3	102
34	Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy. International Journal of Environmental Research and Public Health, 2020, 17, 4417.	1.2	98
35	Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut, 1998, 42, 792-794.	6.1	97
36	Antibiotic Prophylaxis of Bacterial Infections in Cirrhotic Inpatients: a Meta-Analysis of Randomized Controlled Trials. Scandinavian Journal of Gastroenterology, 2003, 38, 193-200.	0.6	97

#	Article	IF	CITATIONS
37	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors. Neuroendocrinology, 2009, 90, 214-219.	1.2	97
38	Atrophic Body Gastritis: Distinct Features Associated withHelicobacter pyloriInfection. Helicobacter, 1997, 2, 57-64.	1.6	94
39	Two-thirds of Atrophic Body Gastritis Patients Have Evidence of Helicobacter pylori Infection. Helicobacter, 2001, 6, 225-233.	1.6	91
40	Occurrence and Risk Factors for Autoimmune Thyroid Disease in Patients with Atrophic Body Gastritis. American Journal of Medicine, 2008, 121, 136-141.	0.6	91
41	Systematic review: impaired drug absorption related to the coâ€administration of antisecretory therapy. Alimentary Pharmacology and Therapeutics, 2009, 29, 1219-1229.	1.9	91
42	Chronic atrophic gastritis: Natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian Society of Gastroenterology [SIGE], and the Italian Society of Internal Medicine [SIMI]. Digestive and Liver Disease, 2019, 51, 1621-1632.	0.4	90
43	Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Alimentary Pharmacology and Therapeutics, 2011, 33, 1361-1369.	1.9	88
44	Endoscopic grading of gastric intestinal metaplasia (EGGIM): a multicenter validation study. Endoscopy, 2019, 51, 515-521.	1.0	86
45	The Eradication of Helicobacter pylori is Affected by Body Mass Index (BMI). Obesity Surgery, 2008, 18, 1450-1454.	1.1	85
46	Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines. Techniques in Coloproctology, 2015, 19, 615-626.	0.8	82
47	The stomach and iron deficiency anaemia: a forgotten link. Digestive and Liver Disease, 2003, 35, 288-295.	0.4	80
48	Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Alimentary Pharmacology and Therapeutics, 2010, 31, 1042-1050.	1.9	80
49	Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?. Alimentary Pharmacology and Therapeutics, 2001, 15, 1555-1561.	1.9	79
50	Micronutrients (Other than iron) and <i>Helicobacter pylori</i> Infection: A Systematic Review. Helicobacter, 2012, 17, 1-15.	1.6	77
51	The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis. Alimentary Pharmacology and Therapeutics, 2002, 16, 1723-1731.	1.9	75
52	Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated withHelicobacter pyloriinfection. Alimentary Pharmacology and Therapeutics, 2001, 15, 1753-1761.	1.9	73
53	Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up. Scandinavian Journal of Gastroenterology, 2015, 50, 856-865.	0.6	70
54	Probiotics in the Treatment of Diverticular Disease. A Systematic Review. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 79-86.	0.5	67

#	Article	IF	CITATIONS
55	High Prevalence of Atrophic Body Gastritis in Patients With Unexplained Microcytic and Macrocytic Anemia. American Journal of Gastroenterology, 1999, 94, 766-772.	0.2	66
56	Treatment of <i>Helicobacter pylori</i> infection in atrophic gastritis. World Journal of Gastroenterology, 2018, 24, 2373-2380.	1.4	66
57	Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2005, 22, 471-481.	1.9	65
58	Treatment of Diverticular Disease of the Colon and Prevention of Acute Diverticulitis: A Systematic Review. Diseases of the Colon and Rectum, 2011, 54, 1326-1338.	0.7	65
59	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy. Neuroendocrinology, 2009, 90, 209-213.	1.2	64
60	Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia. Diabetologia, 1996, 39, 677-686.	2.9	62
61	Early Manifestations of Gastric Autoimmunity in Patients with Juvenile Autoimmune Thyroid Diseases. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4944-4948.	1.8	62
62	A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders. United European Gastroenterology Journal, 2013, 1, 385-393.	1.6	62
63	Systematic review: <i>Heliocobacter pylori</i> infection and impaired drug absorption. Alimentary Pharmacology and Therapeutics, 2009, 29, 379-386.	1.9	61
64	SARS-CoV2 RNA detection in a pancreatic pseudocyst sample. Pancreatology, 2020, 20, 1011-1012.	0.5	59
65	Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review. Journal of Clinical Medicine, 2019, 8, 1032.	1.0	58
66	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:Echocardiography. Neuroendocrinology, 2009, 90, 190-193.	1.2	57
67	Diagnosis and Management of Pernicious Anemia. Current Gastroenterology Reports, 2011, 13, 518-524.	1.1	57
68	Histological recovery and glutenâ€free diet adherence: a prospective 1â€year followâ€up study of adult patients with coeliac disease. Alimentary Pharmacology and Therapeutics, 2014, 40, 639-647.	1.9	57
69	Upper gastrointestinal symptoms in autoimmune gastritis. Medicine (United States), 2017, 96, e5784.	0.4	57
70	Effect of Bombesin on Plasma Insulin, Pancreatic Glucagon, and Gut Glucagon in Man*. Journal of Clinical Endocrinology and Metabolism, 1983, 56, 643-647.	1.8	56
71	Consequences of Helicobacter pylori infection on the absorption of micronutrients. Digestive and Liver Disease, 2002, 34, S72-S77.	0.4	56
72	Iron deficiency anaemia and Helicobacter pylori infection. International Journal of Antimicrobial Agents, 2000, 16, 515-519.	1.1	54

#	Article	IF	CITATIONS
73	First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: When should it be done?. Gastrointestinal Endoscopy, 2001, 53, 443-448.	0.5	54
74	Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: A national survey. Digestive and Liver Disease, 2020, 52, 808-815.	0.4	54
75	Role of Helicobacter pylori infection in pernicious anaemia. Digestive and Liver Disease, 2000, 32, 756-762.	0.4	52
76	Can patient characteristics predict the outcome of endoscopic evaluation of iron deficiency anemia: a multiple logistic regression analysis. Gastrointestinal Endoscopy, 2004, 59, 766-771.	0.5	52
77	Effects of somatostatin on human intestinal lamina propria lymphocytes. Modulation of lymphocyte activation. Journal of Neuroimmunology, 1991, 31, 211-219.	1.1	50
78	Role of Fiber in Symptomatic Uncomplicated Diverticular Disease: A Systematic Review. Nutrients, 2017, 9, 161.	1.7	49
79	Endocrine cell growths in atrophic body gastritis. Critical evaluation of a histological classification. , 1997, 182, 339-346.		48
80	E-cadherin germline mutation carriers: clinical management and genetic implications. Cancer and Metastasis Reviews, 2014, 33, 1081-1094.	2.7	48
81	Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth Journal of Clinical Endocrinology and Metabolism, 1996, 81, 677-683.	1.8	47
82	Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment. Alimentary Pharmacology and Therapeutics, 2004, 19, 663-670.	1.9	46
83	Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. European Journal of Clinical Investigation, 2013, 43, 1147-1155.	1.7	46
84	A current clinical overview of atrophic gastritis. Expert Review of Gastroenterology and Hepatology, 2020, 14, 93-102.	1.4	45
85	Role of Noninvasive Tests (13C-Urea Breath Test and Stool Antigen Test) as Additional Tools in Diagnosis ofHelicobacter PyloriInfection in Patients with Atrophic Body Gastritis. Helicobacter, 2004, 9, 436-442.	1.6	44
86	Extragastric Manifestations of <i>Helicobacter pylori</i> Infection – Other <i>Helicobacters</i> . Helicobacter, 2007, 12, 45-53.	1.6	44
87	Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up. Digestive and Liver Disease, 2011, 43, 295-299.	0.4	43
88	Neurohumoral control of gallbladder motility in healthy subjects and diabetic patients with or without autonomic neuropathy. Digestive Diseases and Sciences, 1990, 35, 1089-1097.	1.1	41
89	Gastric Neuroendocrine Tumors. Neuroendocrinology, 2004, 80, 16-19.	1.2	41
90	<i>Helicobacter pylori</i> infection and drugs malabsorption. World Journal of Gastroenterology, 2014, 20, 10331.	1.4	40

#	Article	IF	CITATIONS
91	Bombesin effects on human GI functions. Peptides, 1985, 6, 113-116.	1.2	39
92	Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity. Regulatory Peptides, 1992, 38, 79-87.	1.9	39
93	Vasoactive intestinal polypeptide modulates the in vitro immunoglobulin a production by intestinal lamina propria lymphocytes. Gastroenterology, 1994, 106, 576-582.	0.6	39
94	Clinical features of symptomatic uncomplicated diverticular disease: a multicenter Italian survey. International Journal of Colorectal Disease, 2012, 27, 1151-1159.	1.0	39
95	Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 677-683.	1.8	39
96	Effects of bombesin on gastrin and gastric acid secretion in patients with duodenal ulcer. Gut, 1983, 24, 231-235.	6.1	38
97	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology, 2009, 90, 203-208.	1.2	38
98	Endoscopic Evaluation of the Upper Gastrointestinal Tract is Worthwhile in Premenopausal Women with Iron-Deficiency Anaemia Irrespective of Menstrual Flow. Scandinavian Journal of Gastroenterology, 2003, 38, 239-245.	0.6	37
99	Lack of specific association between gastric autoimmunity hallmarks and clinical presentations of atrophic body gastritis. World Journal of Gastroenterology, 2005, 11, 5351.	1.4	37
100	High-fibre diet and <i>Lactobacillus paracasei B21060</i> in symptomatic uncomplicated diverticular disease. World Journal of Gastroenterology, 2012, 18, 5918.	1.4	36
101	SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. Journal of Nuclear Medicine, 1996, 37, 1452-6.	2.8	36
102	Oxyntic endocrine cells of hypergastrinaemic patients. Differential response to antrectomy or octreotide Gut, 1996, 38, 668-674.	6.1	35
103	Zollingerâ€Ellison syndrome and antral Gâ€cell hyperfunction in patients with resistant duodenal ulcer disease. Alimentary Pharmacology and Therapeutics, 1994, 8, 87-93.	1.9	35
104	CagA and VacA are Immunoblot Markers of Past Helicobacter pylori Infection in Atrophic Body Gastritis. Helicobacter, 2007, 12, 23-30.	1.6	35
105	After <i>Helicobacter pylori</i> , Genetic Susceptibility to Gastric Carcinoma Revisited. Helicobacter, 2007, 12, 45-49.	1.6	35
106	Artificial neural networks in the recognition of the presence of thyroid disease in patients with atrophic body gastritis. World Journal of Gastroenterology, 2008, 14, 563.	1.4	35
107	Costâ€effectiveness of Endoscopic Surveillance for Gastric Intestinal Metaplasia. Helicobacter, 2010, 15, 221-226.	1.6	35
108	Prevalence and distribution of colonic diverticula assessed with CT colonography (CTC). European Radiology, 2016, 26, 639-645.	2.3	35

#	Article	IF	CITATIONS
109	Treatment of diverticular disease: an update on latest evidence and clinical implications. Drugs in Context, 2018, 7, 1-11.	1.0	35
110	Detection of Gastric Precancerous Conditions in Daily Clinical Practice: A Nationwide Survey. Helicobacter, 2014, 19, 417-424.	1.6	32
111	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. Digestive and Liver Disease, 2019, 51, 1456-1460.	0.4	32
112	CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors. Radiologia Medica, 2022, 127, 691-701.	4.7	32
113	Current Perspectives in Atrophic Gastritis. Current Gastroenterology Reports, 2020, 22, 38.	1.1	31
114	Somatostatin Receptor Localization of Pancreatic Endocrine Tumors. World Journal of Surgery, 1996, 20, 241-244.	0.8	30
115	Low prevalence of idiopathic peptic ulcer disease: An Italian endoscopic survey. Digestive and Liver Disease, 2010, 42, 773-776.	0.4	30
116	Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE). Digestive and Liver Disease, 2017, 49, 595-603.	0.4	29
117	Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment. Alimentary Pharmacology and Therapeutics, 2002, 16, 507-514.	1.9	28
118	Symptom-based approach to colorectal cancer: survey of primary care physicians in Italy. Digestive and Liver Disease, 2003, 35, 869-875.	0.4	28
119	Trends in hospital admission for acute diverticulitis in Italy from 2008 to 2015. Techniques in Coloproctology, 2018, 22, 597-604.	0.8	28
120	Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. Journal of Clinical Medicine, 2019, 8, 910.	1.0	28
121	Helicobacter pylori and functional dyspepsia: an unsolved issue?. World Journal of Gastroenterology, 2014, 20, 8957-63.	1.4	28
122	Thyro-entero-gastric autoimmunity: Pathophysiology and implications for patient management. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101373.	2.2	27
123	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. Oncologist, 2020, 25, 259-265.	1.9	27
124	Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide. Regulatory Peptides, 1993, 47, 307-318.	1.9	26
125	Corpus-predominant gastritis as a risk factor for false-negative13C-urea breath test results. Alimentary Pharmacology and Therapeutics, 2006, 24, 1453-1460.	1.9	26
126	Hypergastrinemia and enterochromaffin-like cell hyperplasia. Yale Journal of Biology and Medicine, 1998, 71, 291-301.	0.2	26

#	Article	IF	CITATIONS
127	Intragastric Ascorbic But Not Uric Acid is Depleted in Relation with the Increased pH in Patients with Atrophic Body Gastritis and H. Pylori Gastritis. Helicobacter, 2003, 8, 300-306.	1.6	25
128	Appropriateness of the indication for upper endoscopy: A meta-analysis. Digestive and Liver Disease, 2010, 42, 122-126.	0.4	25
129	Cell Blood Count Alterations and Patterns of Anaemia in Autoimmune Atrophic Gastritis at Diagnosis: A Multicentre Study. Journal of Clinical Medicine, 2019, 8, 1992.	1.0	25
130	Antral gastrin cell hyperfunction in children. Gastroenterology, 1991, 101, 1547-1551.	0.6	24
131	Appropriateness of the Indication for Colonoscopy. Journal of Clinical Gastroenterology, 2012, 46, 590-594.	1.1	24
132	Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients?. American Journal of Gastroenterology, 1997, 92, 790-4.	0.2	24
133	Efficacy of Lactobacillus paracasei sub. paracasei F19 on abdominal symptoms in patients with symptomatic uncomplicated diverticular disease: a pilot study. Minerva Gastroenterologica E Dietologica, 2011, 57, 13-22.	2.2	24
134	Management of Helicobacter pylori infection: Guidelines of the Italian Society of Gastroenterology (SIGE) and the Italian Society of Digestive Endoscopy (SIED). Digestive and Liver Disease, 2022, 54, 1153-1161.	0.4	24
135	Iron-Deficiency Anemia in Premenopausal Women: Why Not Consider Atrophic Body Gastritis and Helicobacter pylori Role?. American Journal of Gastroenterology, 1999, 94, 3084-3085.	0.2	23
136	Benefit of concomitant gastrointestinal and gynaecological evaluation in premenopausal women with iron deficiency anaemia. Alimentary Pharmacology and Therapeutics, 2008, 28, 422-430.	1.9	23
137	Prevalence of lesions detected at upper endoscopy: An Italian survey. European Journal of Internal Medicine, 2014, 25, 772-776.	1.0	23
138	Autoimmune Gastritis and Gastric Microbiota. Microorganisms, 2020, 8, 1827.	1.6	23
139	Possible contribution of advanced statistical methods (artificial neural networks and linear) Tj ETQq1 1 0.784314 Journal of Gastroenterology, 2005, 11, 5867.	rgBT /Ov 1.4	erlock 10 Tf 5 23
140	Role of small bowel investigation in iron deficiency anaemia after negative endoscopic/histologic evaluation of the upper and lower gastrointestinal tract. Digestive and Liver Disease, 2003, 35, 784-787.	0.4	22
141	Western Blotting of Total Lysate of Helicobacter pylori in Cases of Atrophic Body Gastritis. Clinical Chemistry, 2006, 52, 220-226.	1.5	22
142	Gastric carcinoid in the absence of atrophic body gastritis and with low Ki67 index: a clinical challenge. Scandinavian Journal of Gastroenterology, 2014, 49, 506-510.	0.6	22
143	Gastric acid and pancreatic polypeptide responses to modified sham feeding: indication of an increased basal vagal tone in a subgroup of duodenal ulcer patients Gut, 1985, 26, 776-782.	6.1	21
144	Prevalence and Causes of Hypergastrinemia in Primary Hyperparathyroidism: A Prospective Study ¹ . Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4554-4558.	1.8	21

#	Article	IF	CITATIONS
145	Gastric cancer in patients with type I gastric carcinoids. Gastric Cancer, 2015, 18, 564-570.	2.7	21
146	Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients. Clinical and Translational Gastroenterology, 2017, 8, e215.	1.3	21
147	Occurrence and predictors of metaplastic atrophic gastritis in a nation-wide consecutive endoscopic population presenting with upper gastrointestinal symptoms. European Journal of Gastroenterology and Hepatology, 2018, 30, 1291-1296.	0.8	21
148	CT texture analysis of liver metastases in PNETs versus NPNETs: Correlation with histopathological findings. European Journal of Radiology, 2020, 124, 108812.	1.2	21
149	Seronegative autoimmune atrophic gastritis is more common in elderly patients. Digestive and Liver Disease, 2020, 52, 1310-1314.	0.4	21
150	HLA-DRB1*03 and DRB1*04 are associated with atrophic gastritis in an Italian population. Digestive and Liver Disease, 2010, 42, 854-859.	0.4	20
151	Risk Factors Associated with the Occurrence of Autoimmune Diseases in Adult Coeliac Patients. Gastroenterology Research and Practice, 2018, 2018, 1-6.	0.7	20
152	Incidence of cancer (other than gastric cancer) in pernicious anaemia: A systematic review with meta-analysis. Digestive and Liver Disease, 2018, 50, 780-786.	0.4	20
153	Pancreatic polypeptide response to a protein-rich meal in diabetic patients with and without neuropathy. Journal of Endocrinological Investigation, 1986, 9, 1-4.	1.8	19
154	Intestinal metaplasia surveillance: Searching for the road-map. World Journal of Gastroenterology, 2013, 19, 1523.	1.4	19
155	Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2001, 15, 821-829.	1.9	18
156	Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients. Digestive and Liver Disease, 2002, 34, 270-278.	0.4	18
157	Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollingerâ€Ellison syndrome and antral Gâ€cell hyperfunction. Alimentary Pharmacology and Therapeutics, 1994, 8, 95-104.	1.9	18
158	Endoscopic surveillance at 3 years after diagnosis, according to European guidelines, seems safe in patients with atrophic gastritis in a low-risk region. Digestive and Liver Disease, 2021, 53, 467-473.	0.4	18
159	Common Pitfalls in the Management of Patients with Micronutrient Deficiency: Keep in Mind the Stomach. Nutrients, 2021, 13, 208.	1.7	18
160	Inhibitory effect of somatostatin-14 and some analogues on human natural killer cell activity. Peptides, 1994, 15, 1033-1036.	1.2	17
161	Immunoproteomics of Helicobacter pylori infection in patients with atrophic body gastritis, a predisposing condition for gastric cancer. International Journal of Medical Microbiology, 2011, 301, 125-132.	1.5	16
162	Hospital admission for complicated diverticulitis is increasing in Italy, especially in younger patients: a national database study. Techniques in Coloproctology, 2020, 24, 237-245.	0.8	16

#	Article	IF	CITATIONS
163	Prevalence and Causes of Hypergastrinemia in Primary Hyperparathyroidism: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4554-4558.	1.8	16
164	Management of type-I gastric neuroendocrine neoplasms: A 10-years prospective single centre study. Digestive and Liver Disease, 2022, 54, 890-895.	0.4	16
165	Occurrence and risk factors for benign epithelial gastric polyps in atrophic body gastritis on diagnosis and follow-up. Alimentary Pharmacology and Therapeutics, 2005, 21, 567-574.	1.9	15
166	Single nucleotide polymorphisms related to vitamin B12 serum levels in autoimmune gastritis patients with or without pernicious anaemia. Digestive and Liver Disease, 2015, 47, 285-290.	0.4	15
167	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. Pancreatology, 2019, 19, 1067-1073.	0.5	15
168	Comparison of Endoscopic Techniques in the Management of Type I Gastric Neuroendocrine Neoplasia: A Systematic Review. Gastroenterology Research and Practice, 2021, 2021, 1-6.	0.7	15
169	Long-term octreotide treatment of metastatic carcinoid tumor. Annals of Oncology, 2000, 11, 491-494.	0.6	14
170	Efficacy of longâ€ŧerm therapy with low doses of omeprazole in the control of gastric acid secretion in Zollingerâ€Ellison syndrome patients. Alimentary Pharmacology and Therapeutics, 1993, 7, 167-193.	1.9	14
171	Updated features associated with type 1 gastric carcinoids patients: a single-center study. Scandinavian Journal of Gastroenterology, 2014, 49, 1447-1455.	0.6	14
172	Cost of detecting gastric neoplasia by surveillance endoscopy in atrophic gastritis in Italy: A low risk country. Digestive and Liver Disease, 2017, 49, 291-296.	0.4	14
173	Demographic and clinical features distinguish subgroups of diverticular disease patients: Results from an Italian nationwide registry. United European Gastroenterology Journal, 2018, 6, 926-934.	1.6	14
174	Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs. Pancreatology, 2020, 20, 875-879.	0.5	14
175	Endoscopic Submucosal Dissection of Gastric Neoplastic Lesions: An Italian, Multicenter Study. Journal of Clinical Medicine, 2020, 9, 737.	1.0	14
176	Effects of high in vivo levels of vasoactive intestinal polypeptide on function of circulating lymphocytes in humans. Gastroenterology, 1990, 98, 1693-1698.	0.6	13
177	Effects of Recent, Short-Term Hyperglycemia on Responses to Hypoglycemia in Humans: Relevance to the Pathogenesis of Hypoglycemia Unawareness and Hyperglycemia-Induced Insulin Resistance. Diabetes, 1995, 44, 513-519.	0.3	13
178	Risk factors associated with osteoporosis in a cohort of prospectively diagnosed adult coeliac patients. United European Gastroenterology Journal, 2018, 6, 1161-1168.	1.6	13
179	Cameron lesions: A still overlooked diagnosis. Case report and systematic review of literature. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 604-609.	0.7	13
180	Autoantibodies Toward ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase Are Reliable Serological Pre-endoscopic Markers of Corpus Atrophic Gastritis. Clinical and Translational Gastroenterology, 2020, 11, e00240.	1.3	13

#	Article	IF	CITATIONS
181	Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia, 1994, 37, 1265-1276.	2.9	13
182	Medical Treatment of Antral Gastrin Cell Hyperfunction: Role of Nonantisecretory Therapy. Digestion, 1990, 46, 65-71.	1.2	12
183	Helicobacter pylori Infection in Children with Antral Gastrin Cell Hyperfunction. Journal of Pediatric Gastroenterology and Nutrition, 1994, 18, 152-158.	0.9	12
184	Hypersecretory duodenal ulcer and Helicobacter pylori infection: for-year follow-up study. Digestive and Liver Disease, 2000, 32, 119-124.	0.4	12
185	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. Digestive and Liver Disease, 2021, 53, 367-374.	0.4	12
186	Gastrectomy for stage IV gastric cancer: a comparison of different treatment strategies from the SEER database. Scientific Reports, 2021, 11, 7150.	1.6	12
187	Peptic ulcer and duodenal stenosis: role of Helicobacter pylori infection. The Italian Journal of Gastroenterology, 1995, 27, 26-8.	0.1	12
188	Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide. Journal of Nuclear Medicine, 1997, 38, 886-7.	2.8	12
189	Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours. Italian Journal of Gastroenterology and Hepatology, 1999, 31, 23-7.	0.5	12
190	Cyclic antibiotic therapy for diverticular disease: a critical reappraisal. Journal of Gastrointestinal and Liver Diseases, 2010, 19, 295-302.	0.5	12
191	Antral gastrin cell hyperfunction and Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 1996, 10, 607-615.	1.9	11
192	Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs. Alimentary Pharmacology and Therapeutics, 1998, 12, 463-468.	1.9	11
193	Duodenal Ulcer Relapse Is Not Always Associated with Recurrence of H. pylori Infection: A Prospective Three-Year Follow-Up Study. Helicobacter, 1999, 4, 213-217.	1.6	11
194	Unawareness of gastrointestinal symptomatology in adult coeliac patients with unexplained iron-deficiency anaemia presentation. Alimentary Pharmacology and Therapeutics, 2006, 23, 915-921.	1.9	11
195	No higher risk for colorectal cancer in atrophic gastritis-related hypergastrinemia. Digestive and Liver Disease, 2012, 44, 793-797.	0.4	11
196	ATPase4A Autoreactivity and Its Association With Autoimmune Phenotypes in the Type 1 Diabetes Genetics Consortium Study. Diabetes Care, 2015, 38, S29-S36.	4.3	11
197	Upper and lower gastrointestinal causes of iron deficiency anemia in elderly compared with adult outpatients. Minerva Gastroenterologica E Dietologica, 2010, 56, 397-404.	2.2	11
198	Systematic review and meta-analysis: Artificial intelligence for the diagnosis of gastric precancerous lesions and Helicobacter pylori infection. Digestive and Liver Disease, 2022, 54, 1630-1638.	0.4	11

#	Article	IF	CITATIONS
199	Relationship between fundic endocrine cells and gastric acid secretion in hypersecretory duodenal ulcer diseases. Alimentary Pharmacology and Therapeutics, 1998, 12, 779-788.	1.9	10
200	High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis. Digestive and Liver Disease, 2009, 41, 555-558.	0.4	10
201	Increasing trend in admission rates and costs for acute diverticulitis during 2005–2015: real-life data from the Abruzzo Region. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481879150.	1.4	10
202	Recent advances in understandingÂand managing diverticulitis. F1000Research, 2018, 7, 971.	0.8	10
203	Castroesophageal reflux symptoms and microscopic esophagitis in a cohort of consecutive patients affected by atrophic body gastritis: a pilot study. Scandinavian Journal of Gastroenterology, 2019, 54, 35-40.	0.6	10
204	Relationship between Persistent Gastrointestinal Symptoms and Duodenal Histological Findings after Adequate Gluten-Free Diet: A Gray Area of Celiac Disease Management in Adult Patients. Nutrients, 2021, 13, 600.	1.7	10
205	Gastric microbiota composition in patients with corpus atrophic gastritis. Digestive and Liver Disease, 2021, 53, 1580-1587.	0.4	10
206	Pseudopyloric Metaplasia Is Not Associated With the Development of Gastric Cancer. American Journal of Gastroenterology, 2021, 116, 1859-1867.	0.2	10
207	Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger?Ellison syndrome during omeprazole treatment. Histopathology, 1992, 21, 359-363.	1.6	9
208	Iron Deficiency Anaemia Caused by Nonspecific (Idiopathic) Small Bowel Ulceration: An Uncommon Presentation of an Uncommon Disease. Canadian Journal of Gastroenterology & Hepatology, 2002, 16, 855-859.	1.8	9
209	Omeprazole versus famotidine in the shortâ€ŧerm treatment of duodenal ulcer disease. Alimentary Pharmacology and Therapeutics, 1992, 6, 469-478.	1.9	9
210	Helicobacter pyloriimmunoproteomics in gastric cancer and gastritis of the carcinoma phenotype. Expert Review of Proteomics, 2010, 7, 239-248.	1.3	9
211	Gastric precancerous conditions and Helicobacter pylori infection in dyspeptic patients with or without endoscopic lesions. Scandinavian Journal of Gastroenterology, 2016, 51, 1294-1298.	0.6	9
212	Time trend occurrence of duodenal intraepithelial lymphocytosis and celiac disease in an open access endoscopic population. United European Gastroenterology Journal, 2017, 5, 811-818.	1.6	9
213	Narrow band imaging characteristics of gastric polypoid lesions: a single-center prospective pilot study. European Journal of Gastroenterology and Hepatology, 2020, 32, 701-705.	0.8	9
214	Single photon emission computerized tomography increases the sensitivity of indium-111-pentetreotide scintigraphy in detecting abdominal carcinoids. Anticancer Research, 1997, 17, 1753-6.	0.5	9
215	Modulatory Effects of Somatostatin and Vasoactive Intestinal Peptide on Human Intestinal Lymphocytes. Annals of the New York Academy of Sciences, 1990, 594, 408-410.	1.8	8
216	Assessing the severity of atrophic gastritis. European Journal of Gastroenterology and Hepatology, 2007, 19, 1059-1063.	0.8	8

#	Article	IF	CITATIONS
217	Is interleukinâ \in I genotyping useful for the clinical management of patients with atrophic body gastritis?. Alimentary Pharmacology and Therapeutics, 2008, 27, 355-365.	1.9	8
218	Role of gastritis pattern on Helicobacter pylori eradication. Internal and Emergency Medicine, 2012, 7, 517-522.	1.0	8
219	Thyro-gastric autoimmunity in patients with differentiated thyroid cancer: a prospective study. Endocrine, 2015, 49, 163-169.	1.1	8
220	The Trends of Complicated Acute Colonic Diverticulitis—A Systematic Review of the National Administrative Databases. Medicina (Lithuania), 2019, 55, 744.	0.8	8
221	Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors. Endocrine, 2022, 76, 484-490.	1.1	8
222	HYPERGASTRINAEMIA AFTER LONG-TERM H2-BLOCKER TREATMENT. Lancet, The, 1987, 330, 1466-1467.	6.3	7
223	Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate. Neurology, 2016, 87, 952-953.	1.5	7
224	A single vial is enough in the absence of endoscopic suspected intestinal metaplasia – less is more!. Scandinavian Journal of Gastroenterology, 2019, 54, 673-677.	0.6	7
225	Measurement of Autoantibodies to Gastric H+,K+-ATPase (ATP4A/B) Using a Luciferase Immunoprecipitation System (LIPS). Methods in Molecular Biology, 2019, 1901, 113-131.	0.4	7
226	Omeprazole in patients with mild or moderate reflux esophagitis induces lower relapse rates than ranitidine during maintenance treatment. Hepato-Gastroenterology, 1998, 45, 742-51.	0.5	7
227	Endoscopic evaluation of the upper gastrointestinal tract is worthwhile in premenopausal women with iron-deficiency anaemia irrespective of menstrual flow. Scandinavian Journal of Gastroenterology, 2003, 38, 239-45.	0.6	7
228	Gender-sex differences in autoimmune atrophic gastritis. Translational Research, 2022, 248, 1-10.	2.2	7
229	Reversible Sustained Increase of Gastrin and Gastric Acid Secretion in a Subgroup of Duodenal Ulcer Patients on Long-Term Treatment with H2 Antagonists. Journal of Clinical Gastroenterology, 1991, 13, 284-290.	1.1	6
230	Endoscopic appearances of polypoid type 1 gastric microcarcinoids by narrow-band imaging. European Journal of Gastroenterology and Hepatology, 2016, 28, 463-468.	0.8	6
231	A case of Barrett's oesophagus in pernicious anaemia: acid is not the only culprit!. Therapeutic Advances in Gastroenterology, 2016, 9, 419-421.	1.4	6
232	Treatment of diverticular disease, targeting symptoms or underlying mechanisms. Current Opinion in Pharmacology, 2018, 43, 124-131.	1.7	6
233	Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry. United European Gastroenterology Journal, 2019, 7, 815-824.	1.6	6
234	Diagnostic Accuracy of EndoFaster® and Narrow-Band Imaging Endoscopy in Patients with Impaired Gastric Acid Secretion: A Real-Time Prospective Study. Gastroenterology Research and Practice, 2021, 2021, 1-8.	0.7	6

#	ARTICLE	IF	CITATIONS
235	Role of Dietary Habits in the Prevention of Diverticular Disease Complications: A Systematic Review. Nutrients, 2021, 13, 1288.	1.7	6
236	Is proliferative colonic disease presentation changing?. World Journal of Gastroenterology, 2012, 18, 6614.	1.4	6
237	Human circular colonic smooth muscle cells possess active somatostatin receptors. Italian Journal of Gastroenterology and Hepatology, 1998, 30, 505-9.	0.5	6
238	Metformin plus proton pump inhibitors therapy: the cobalamin deficiency challenge. European Review for Medical and Pharmacological Sciences, 2015, 19, 2501-2.	0.5	6
239	Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia: A Case Series. Journal of Clinical Medicine, 2022, 11, 1641.	1.0	6
240	Dose-Response Effect of Somatostatin44 on Human Basal Pancreatic Hormones. Pancreas, 1987, 2, 551-556.	0.5	5
241	Modulation of Growth of Human Gastric Enterochromaffin-Like Cells. Digestion, 1996, 57, 15-16.	1.2	5
242	Co-existence of hyperparathyroidism, hypergastrinaemia and multiple gastric carcinoids is not always due to incomplete expression of the MEN-1 syndrome. Digestive and Liver Disease, 2003, 35, 585-589.	0.4	5
243	Are clinical features able to predict Helicobacter pylori gastritis patterns? Evidence from tertiary centers. Internal and Emergency Medicine, 2014, 9, 841-845.	1.0	5
244	Pernicious Anemia: Time to Justify Endoscopic Monitoring?. Clinical Gastroenterology and Hepatology, 2016, 14, 322.	2.4	5
245	Surgical treatment of acute complicated diverticulitis in the elderly. Minerva Chirurgica, 2020, 74, 465-471.	0.8	5
246	Distinguishing features between patients with acute diverticulitis and diverticular bleeding: Results from the REMAD registry. Digestive and Liver Disease, 2021, 53, 202-209.	0.4	5
247	Pre-endoscopic screening for Helicobacter pylori and celiac disease in young anemic women. World Journal of Gastroenterology, 2009, 15, 2748.	1.4	5
248	Effects of recent, short-term hyperglycemia on responses to hypoglycemia in humans. Relevance to the pathogenesis of hypoglycemia unawareness and hyperglycemia-induced insulin resistance. Diabetes, 1995, 44, 513-519.	0.3	5
249	Long-term intensive insulin therapy in IDDM: effects on HbA1 c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia. Diabetologia, 1996, 39, 677-686.	2.9	5
250	Effect of Vasoactive Intestinal Peptide Neuropeptide on Natural Killer Activity from Peripheral Blood Lymphocytes of Normal Subjects. Annals of the New York Academy of Sciences, 1990, 594, 420-422.	1.8	4
251	Gut neuropeptides and the immune system. Advances in Neuroimmunology, 1991, 1, 173-179.	1.8	4
252	Relationship between omeprazole pre-treatment and successfull eradication rate on H. pylori (Hp) infection. Gastroenterology, 1995, 108, A68.	0.6	4

#	Article	IF	CITATIONS
253	Absorption of the oral iron preparation ferrous acetyl transferrin in achlorhydric patients: a pilot study. Current Therapeutic Research, 1996, 57, 544-551.	0.5	4
254	DXA vs. QCT for subclinical celiac disease patients. Acta Diabetologica, 2003, 40, s174-s176.	1.2	4
255	Probiotics and Diverticular Disease. Journal of Clinical Gastroenterology, 2016, 50, S159-S160.	1.1	4
256	Occurrence of Acute Oesophageal Necrosis (Black Oesophagus) in a Single Tertiary Centre. Journal of Clinical Medicine, 2019, 8, 1532.	1.0	4
257	Successful coping with SARS-CoV-2 infection of adult celiac patients assessed by telemedicine. Digestive and Liver Disease, 2021, 53, 391-393.	0.4	4
258	Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. Journal of Gastrointestinal Oncology, 2021, 12, 845-855.	0.6	4
259	Evidence that bombesin releases extragastric gastrin in man. Regulatory Peptides, 1985, 11, 43-49.	1.9	3
260	Evidence that H. pylori eradication is not always associated with peptic ulcer healing. Gastroenterology, 1995, 108, A46.	0.6	3
261	Thyroxine in Goiter,H. pyloriInfection, and Gastritis. New England Journal of Medicine, 2006, 355, 1177-1177.	13.9	3
262	Chronic Idiophatic Urticaria and <i>Helicobacter Pylori</i> : A Specific Pattern of Gastritis and Urticaria Remission after <i>Helicobacter Pylori</i> Eradication. International Journal of Immunopathology and Pharmacology, 2012, 25, 765-770.	1.0	3
263	H. pylori negative MALT lymphoma patients successfully treated with antibiotics: doubts about their H. pylori negativity. Gut, 2006, 55, 1669; author reply 1669.	6.1	3
264	Endoscopic diagnosis of gastric intestinal metaplasia in patients with autoimmune gastritis using narrow-band imaging: does pseudopyloric metaplasia muddy the waters?. Endoscopy International Open, 2022, 10, E434-E440.	0.9	3
265	NEUROTENSIN AND THE DUMPING SYNDROME. Lancet, The, 1981, 317, 1209.	6.3	2
266	Peptides of the APUD system in amphibian skins. Peptides, 1985, 6, 203-208.	1.2	2
267	Maintenance Treatment with H ₂ Receptor Antagonists for Duodenal Ulcer Disease: Toward a Rational Use. Digestive Diseases, 1993, 11, 228-238.	0.8	2
268	Duodenal ulcer and Helicobacter pylori: Relapse and recurrence in a long-term study. Gastroenterology, 1998, 114, A219.	0.6	2
269	Timing and sampling in surveillance of premalignant gastric lesions. Gut, 2002, 51, 896-897.	6.1	2
270	Large hiatal hernia is a underdiagnosed disease in patients with iron deficiency anemia. Gastroenterology, 2003, 124, A627.	0.6	2

#	Article	IF	CITATIONS
271	Italian Guidelines. Journal of Clinical Gastroenterology, 2016, 50, S44-S46.	1.1	2
272	Improving basic skills in celiac-like disease diagnosis: a case report. BMC Gastroenterology, 2018, 18, 162.	0.8	2
273	[18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia. Journal of Endocrinological Investigation, 2021, 44, 811-818.	1.8	2
274	Prevalence of Segmental Colitis Associated with Colonic Diverticulosis in a Prospective Cohort of Patients Who Underwent Colonoscopy in a Tertiary Center. Journal of Clinical Medicine, 2022, 11, 530.	1.0	2
275	Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study. Italian Journal of Gastroenterology and Hepatology, 1997, 29, 501-6.	0.5	2
276	Effect of bombesin (BBS)-stimulated gastrin (G) on gastric acid secretion (GAS) in normal subjicts (N) and duodenal ulcer patients (DU). Regulatory Peptides, 1980, 1, S24.	1.9	1
277	Loss of Efficacy of Famotidine in the Control of Gastric Acid Secretion in Patients with Zollinger-Ellison Syndrome Reversed by Omeprazole. Scandinavian Journal of Gastroenterology, 1989, 24, 180-180.	0.6	1
278	Somatostatin Infused during Acute Pancreatitis Retains Its Biological Activity. Pancreas, 1989, 4, 674-679.	0.5	1
279	Acid secretion was not reduced by H. Pylori (HP) eradication in hypersecretory duodenal ulcer (HDU) and antral G cell hyperplasia (AGCH) patients. Gastroenterology, 1998, 114, A57.	0.6	1
280	PREVALENCE, INCIDENCE AND RISK FACTORS FOR GASTRIC NEOPLASTIC LESIONS IN PATIENTS WITH ATROPHIC BODY GASTRITIS. Digestive and Liver Disease, 2009, 41, S116-S117.	0.4	1
281	P.06.2 IN ADULT COELIAC DISEASE HISTOLOGICAL FOLLOW-UP SEEMS TO BE SATISFACTORY AFTER 2 YEARS OF GLUTEN FREE DIET. Digestive and Liver Disease, 2019, 51, e213.	0.4	1
282	Editorial: lymphocytic gastritis and its relationships with other gastrointestinal disorders. Alimentary Pharmacology and Therapeutics, 2021, 54, 1354-1355.	1.9	1
283	Bombesin, Trypsin, and Chronic Pancreatitis. Gastroenterology, 1984, 86, 1631.	0.6	0
284	Relationship between hyperfunction of antral G cells (AGCH) and autonomic neuropathy (AN) in diabetic patients. Regulatory Peptides, 1992, 40, 108.	1.9	0
285	Bombesin (BBS) sensibility and intragastric pH in duodenal ulcer (DU) patients: A comparison with antral G cell hyperfunction (AGCH). Regulatory Peptides, 1992, 40, 127.	1.9	0
286	Relationship between Helicobacter pylory infection and traditional risk factors in 12 months follow up duodenal ulcer. Gastroenterology, 1995, 108, A81.	0.6	0
287	Combining imaging and surgical procedures in localising GEP tumors does not improve the curability of this syndromes. Gastroenterology, 1995, 108, A950.	0.6	0
288	Different values of fasting gastrinemia are associated to different pattern of ECL proliferation in human. Gastroenterology, 1995, 108, A988.	0.6	0

#	Article	IF	CITATIONS
289	High omeprazole (OMP) dosage triple therapy is better than dual therapy in the eradication of H. pylori in duodenal ulcer (DU) patients. Gastroenterology, 1998, 114, A100.	0.6	0
290	Prevalence of gastric carcinoid and enterochromaffin-like (ECL) dysplastic lesions in atrophic body gastritis (ABG) patients. Gastroenterology, 1998, 114, A639.	0.6	0
291	Hypergastrinemia and primary hyperparathyroidism: A consecutive study. Gastroenterology, 1998, 114, A1166.	0.6	0
292	3412 A standard protocol of biopsies during upper gi endoscopy (ugie) improve the diagnosis in patients with iron deficency anemia (ida) Gastrointestinal Endoscopy, 2000, 51, AB85.	0.5	0
293	Gi diseases causing iron malabsorption are more frequent than GI bleeding lesions in iron deficiency anemia (IDA) patients: A prospective study. Gastroenterology, 2000, 118, A458.	0.6	0
294	Increased intragastric pH and reduced gastric juice ascorbic acid may be related with iron deficiency anemia in patients with atrophic body gastritis (ABG) and pangastritis (PG). Digestive and Liver Disease, 2001, 33, A89.	0.4	0
295	Of Bacteria, Acid, and Blood. Gastroenterology, 2005, 129, 1139-1140.	0.6	0
296	Symptomatic characterization of uncomplicated colon diverticular disease. Digestive and Liver Disease, 2006, 38, S177-S178.	0.4	0
297	OC3.02.8 BODY MASS INDEX (BMI) AFFECTS THE ERADICATION RATE OF HELICOBACTER PYLORI. Digestive and Liver Disease, 2008, 40, S41.	0.4	0
298	OC3.08.3 POPULATION-BASED STUDY ON SYMPTOMATIC CHARACTERIZATION OF UNCOMPLICATED COLON DIVERTICULAR DISEASE: A PRELIMINARY REPORT FROM DIVERTICULAR DISEASE ITALIAN GROUP. Digestive and Liver Disease, 2008, 40, S59.	0.4	0
299	PA.185 EFFICACY OF LACTOBACILLUS PARACASEI F19 IN THE TREATMENT OF SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD) OF THE COLON. Digestive and Liver Disease, 2008, 40, S143.	0.4	0
300	Endoscopic Management of Type I Gastric Carcinoid and Recurrence Rate. Gastrointestinal Endoscopy, 2009, 69, AB112.	0.5	0
301	AUTOIMMUNITY SUSCEPTIBILITY GENOTYPE HLA-DRB1 OCCURS IN PATIENTS WITH ATROPHIC BODY GASTRITIS IRRESPECTIVE OF HELICOBACTER PYLORI INFECTION. Digestive and Liver Disease, 2009, 41, S15.	0.4	0
302	OC.04.3: TYPE I GASTRIC CARCINOIDS: A PROSPECTIVE STUDY ON ENDOSCOPICMANAGEMENT AND RECURRENCE RATE. Digestive and Liver Disease, 2011, 43, S126.	0.4	0
303	P.1.53: HYPERGASTRINEMIA DUE TO ATROPHIC BODY GASTRITIS AND RISK OF COLORECTAL NEOPLASIA: A CASE-CONTROL STUDY. Digestive and Liver Disease, 2011, 43, S166.	0.4	0
304	P.1.110: CLINICAL PATTERNS CAN DISTINGUISH DIVERTICULAR DISEASE FROM IRRITABLE BOWEL SYNDROME: A CASE-CASE MATCHING STUDY. Digestive and Liver Disease, 2011, 43, S184.	0.4	0
305	Letter: gastric cancer and pernicious anaemia ―often <i> <scp>H</scp>elicobacter pylori</i> in disguise; authors' reply. Alimentary Pharmacology and Therapeutics, 2013, 37, 765-766.	1.9	0
306	Editorial: mucosal healing and adherence to the gluten-free diet in coeliac disease - authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 1242-1242.	1.9	0

#	Article	IF	CITATIONS
307	OC.18.2 LOW ADHERENCE TO SYDNEY SYSTEM DECREASES DETECTION RATE OF GASTRIC PRECANCEROUS LESIONS IN DAILY ROUTINE PRACTICE: A NATIONWIDE SURVEY. Digestive and Liver Disease, 2014, 46, S39.	0.4	0
308	P.06.4 ADULT CELIAC PATIENTS ADHERENCE TO A FOLLOW-UP PROGRAM IN THE FIRST YEAR OF GLUTEN-FREE DIET: A SINGLE CENTER STUDY. Digestive and Liver Disease, 2016, 48, e154.	0.4	0
309	OC.07.5 GASTROINTESTINAL SYMPTOMS AND DYSPEPSIA IN AUTOIMMUNE GASTRITIS: AN OVERLOOKED OCCURRENCE. Digestive and Liver Disease, 2016, 48, e97.	0.4	0
310	Letter: gastric cancer and pernicious anaemia - only a minority of UK pernicious anaemia patients have had a gastroscopy - authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 1107-1108.	1.9	0
311	Role of endoscopic surveillance for intestinal metaplasia limited to the antrum. Gastrointestinal Endoscopy, 2016, 84, 875-876.	0.5	0
312	OC.08.3 DYSPEPTIC PATIENTS WITH NEGATIVE GASTROSCOPY HAVE HIGHER PREVALENCE OF H. PYLORI INFECTION THAN PATIENTS WITH ENDOSCOPIC LESIONS. Digestive and Liver Disease, 2016, 48, e100.	0.4	0
313	Symbiotics, Probiotics, and Fiber Diet in Diverticular Disease. , 2016, , 501-514.		0
314	P.01.3: Gastro-Esophageal Reflux (GER) Symptoms and Esophageal Lesions in Patients with Atrophic Body Gastritis. Digestive and Liver Disease, 2017, 49, e132.	0.4	0
315	P.02.4: Efficacy of Bismuth-Based Helicobacter Pylori Treatment in Patients with Atrophic Body Gastritis. Digestive and Liver Disease, 2017, 49, e139.	0.4	0
316	P.12.15: Preliminary Results of 3 Years Follow-Up According to Maps Guidelines in Atrophic Gastritis Patients. Digestive and Liver Disease, 2017, 49, e218.	0.4	0
317	OC.09.1: Autoantibodies Against Atp4A And Atp4B Subunits Of Gastric Proton Pump H+,K+-Atpase Are Reliable Serological Markers Of Gastric Body Atrophy. Digestive and Liver Disease, 2017, 49, e99.	0.4	0
318	Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms. Gastroenterology, 2017, 152, S669.	0.6	0
319	Diverticular disease: myths and facts. Minerva Gastroenterology, 2017, 63, 97-98.	0.3	0
320	P.05.8 TRENDS IN HOSPITAL ADMISSION FOR ACUTE DIVERTICULITIS IN ITALY FROM 2008 TO 2015. Digestive and Liver Disease, 2018, 50, e168-e169.	0.4	0
321	P.10.12 AUTOIMMUNE DISEASES IN ADULT COELIAC PATIENTS: POTENTIAL RISK FACTORS ASSOCIATED WITH THEIR OCCURRENCE. Digestive and Liver Disease, 2018, 50, e232-e233.	0.4	0
322	P.05.11 FEATURES OF ABDOMINAL PAIN MAY DISTINGUISH PATIENTS WITH PREVIOUS DIVERTICULITIS FROM PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE: RESULTS FROM THE ITALIAN REGISTRY OF DIVERTICULAR DISEASE (REMAD). Digestive and Liver Disease, 2018, 50, e170.	0.4	0
323	P.01.1 RED BLOOD CELL LINE ALTERATIONS AT THE TIME OF DIAGNOSIS OF AUTOIMMUNE ATROPHIC GASTRITIS: AN ITALIAN MULTICENTRE CROSS-SECTIONAL STUDY. Digestive and Liver Disease, 2019, 51, e132.	0.4	0
324	Mesalamine (5-ASA) for the prevention of recurrent diverticulitis (Review). Techniques in Coloproctology, 2019, 23, 597-599.	0.8	0

#	Article	IF	CITATIONS
325	P.02.8 USE OF DRUGS PREDISPOSING TO ACUTE DIVERTICULITIS OR BLEEDING IN PATIENTS WITH DIVERTICULAR DISEASE: RESULTS FROM ITALIAN NATIONWIDE REGISTRY (REMAD). Digestive and Liver Disease, 2019, 51, e150-e151.	0.4	0
326	P.03.1 PROGNOSTIC IMPACT OF TUMOR BURDEN IN STAGE IV NEUROENDOCRINE NEOPLASIA: COMPARISON BETWEEN PANCREATIC AND GASTROINTESTINAL LOCALIZATIONS. Digestive and Liver Disease, 2019, 51, e163.	0.4	0
327	P.02.23 DEMOGRAPHIC AND CLINICAL FACTORS ASSOCIATED WITH PHARMACOLOGICAL TREATMENTS IN DIVERTICULAR DISEASE: RESULTS FROM THE REMAD REGISTRY. Digestive and Liver Disease, 2019, 51, e157.	0.4	0
328	P.01.15 TUMOUR TYPE AND SIZE ARE PROGNOSTIC FACTORS IN GASTRIC NEUROENDOCRINE NEOPLASIA: A MULTICENTRE RETROSPECTIVE STUDY. Digestive and Liver Disease, 2019, 51, e139-e140.	0.4	0
329	P.01.14 CURRENT PRACTICE OF GASTROENTEROLOGISTS IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION IN ITALY: DATA FROM THE ITALIAN REGISTRY ON H. PYLORI TREATMENT. Digestive and Liver Disease, 2019, 51, e139.	0.4	0
330	P.03.12 TEXTURE ANALYSIS ON CONTRAST-ENHANCED COMPUTED TOMOGRAPHY IN LIVER METASTASES FROM PANCREATIC AND NON-PANCREATIC NEUROENDOCRINE NEOPLASIA. Digestive and Liver Disease, 2019, 51, e168-e169.	0.4	0
331	P.01.32 PROBIOTIC SUPPLEMENTATION IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION IN ITALY: DATA FROM THE ITALIAN REGISTRY ON H. PYLORI TREATMENT. Digestive and Liver Disease, 2019, 51, e146.	0.4	0
332	P.05.38 AND WHEN NBI DOESN'T SHOWGASTRIC INTESTINAL METAPLASIA: DO WE STILL NEED TO SEPARATE BIOPSY SAMPLES INTO DIFFERENT VIALS?. Digestive and Liver Disease, 2019, 51, e200.	0.4	0
333	Do Alterations in Bone Mineral Density Go Beyond Borders in Adults With Celiac Disease?. Clinical Gastroenterology and Hepatology, 2020, 18, 750.	2.4	0
334	T01.01.2 GASTRIC CANCER OCCURS AT 3-YEARS ENDOSCOPIC SURVEILLANCE IN LOW RISK ATROPHIC GASTRITIS PATIENTS. Digestive and Liver Disease, 2020, 52, S52.	0.4	0
335	T02.01.18 USE OF PROBIOTICS IN THE HELICOBACTER PYLORI ERADICATION IN ITALY: DATA FROM THE "ITALI. REGISTRY―ON H. PYLORI TREATMENT. Digestive and Liver Disease, 2020, 52, S80-S81.	AN 0.4	0
336	T03.01.15 SECOND PRIMARY NEOPLASMS IN PATIENTS WITH GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NEN): DATA FROM A RETROSPECTIVE IT.A.NET STUDY. Digestive and Liver Disease, 2020, 52, S100-S101.	0.4	0
337	TO4.02.1 NUTRITIONAL CHARACTERISTICS OF PATIENTS WITH DIVERTICULAR DISEASE: RESULTS FROM THE REMAD REGISTRY. Digestive and Liver Disease, 2020, 52, S127-S128.	0.4	0
338	Medical care of atrophic gastritis patients during COVID-19 pandemic: Results of telemedicine in a referral center. Digestive and Liver Disease, 2020, 52, 1087-1089.	0.4	0
339	Gastrointestinal endoscopy can be safely performed during pandemic SARS-CoV-2 infection in Central Italy. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	0.8	0
340	Endoscopic Resection of Type I Gastric Neuroendocrine Neoplasia: A Systematic Review. , 2021, 53, .		0
341	Is There an Optimal Age Threshold for Searching for Intestinal Metaplasia on Gastric Mucosa in Western Populations?. GE Portuguese Journal of Gastroenterology, 2021, 28, 398-402.	0.3	0
342	OC.08.7 USEFULLNESS OF 68-GALLIUM PET IN TYPE I GASTRIC NEUROENDOCRINE NEOPLASIA. Digestive and Liver Disease, 2021, 53, S126.	0.4	0

#	Article	IF	CITATIONS
343	AF.20 REAL WORLD STUDY ON MANAGEMENT OF TYPE-I GASTRIC NEUROENDOCRINE NEOPLASMS: A SINGLE CENTER'S EXPERIENCE. Digestive and Liver Disease, 2021, 53, S146.	0.4	0
344	Perioperative Chemotherapy with FLOT Scheme in Resectable Gastric Adenocarcinoma: A Preliminary Correlation between TRG and Radiomics. Applied Sciences (Switzerland), 2021, 11, 9211.	1.3	0
345	Type 1 gastric carcinoids: Efficacy and safety of endoscopic management Journal of Clinical Oncology, 2010, 28, e14577-e14577.	0.8	0
346	ENDOSCOPIC GRADING FOR GASTRIC INTESTINAL METAPLASIA (EGGIM): A MULTICENTRE VALIDATION STUDY. , 2018, 50, .		0
347	OCCURRENCE OF GASTRIC PRECANCEROUS CONDITIONS IN A NATION-WIDE CONSECUTIVE ENDOSCOPIC POPULATION PRESENTING WITH UPPER GASTROINTESTINAL SYMPTOMS. Endoscopy, 2018, 50, .	1.0	0
348	High Concordance between Trained Nurses and Gastroenterologists in Evaluating Recordings of Small Bowel Video Capsule Endoscopy (VCE). Journal of Gastrointestinal and Liver Diseases, 2019, 27, 127-131.	0.5	0
349	NARROW BAND IMAGING CHARACTERISTICS OF POLYPOID GASTRIC LESIONS: A SINGLE CENTER PROSPECTIVE STUDY. , 2019, 51, .		0
350	DIAGNOSTIC ACCURACY OF ENDOFASTER COMPARED TO HISTOLOGY FOR CHRONIC ATROPHIC GASTRITIS USING NARROW BAND IMAGING (NBI) TARGETED BIOPSIES: A REAL-TIME PROSPECTIVE STUDY. Endoscopy, 2019, 51, .	1.0	0
351	GASTRIC CANCER OCCURS AT 3-YEARS ENDOSCOPIC SURVEILLANCE IN LOW RISK ATROPHIC GASTRITIS PATIENTS. , 2020, 52, .		0
352	High concordance between trained nurses and gastroenterologists in evaluating recordings of small bowel video capsule endoscopy (VCE). Journal of Gastrointestinal and Liver Diseases, 2018, 27, 271.	0.5	0
353	DOES ARTIFICIAL INTELLIGENCE ASSIST ENDOSCOPISTS TO EASIER DIAGNOSE GASTRIC PRECANCEROUS LESIONS AND HELICOBACTER-PYLORI INFECTION? A SYSTEMATIC-REVIEW AND META-ANALYSIS. Endoscopy, 2022, 54, .	1.0	0
354	EFFICACY OF AGGRESSIVE PERIPROCEDURAL HYDRATION IN THE PREVENTION OF POST-ERCP PANCREATITIS: AN OBSERVATIONAL STUDY. Endoscopy, 2022, 54, .	1.0	0
355	INCIDENCE OF GASTRIC NEOPLASTIC LESIONS AT LONG-TERM FOLLOW-UP IN PATIENTS WITH AUTOIMMUNE ATROPHIC GASTRITIS. Endoscopy, 2022, 54, .	1.0	0
356	ENDOSCOPIC SURVEILLANCE IN AUTOIMMUNE GASTRITIS: 3-YEAR FOLLOW-UP SEEMS APPROPRIATE. Endoscopy, 2022, 54, .	1.0	0
357	OC.07.5 AUTOIMMUNE ATROPHIC GASTRITIS IN COELIAC DISEASE: ARE THERE ANY DISTINCTIVE FEATURES?. Digestive and Liver Disease, 2022, 54, S86.	0.4	0
358	T.03.1 IMPACT OF GENDER ON CLINICAL MANIFESTATIONS OF COELIAC DISEASE AT THE TIME OF DIAGNOSIS AND FOLLOW-UP. Digestive and Liver Disease, 2022, 54, S124.	0.4	0
359	OC.03.5 ENDOFASTER AND EGGIM FOR THE DIAGNOSIS OF GASTRIC PRENEOPLASTIC LESIONS AND HELICOBACTER PYLORI INFECTION. Digestive and Liver Disease, 2022, 54, S76.	0.4	0
360	OC.07.1 IN PATIENTS WITH AUTOIMMUNE GASTRITIS PATIENTS, THE USE OF PROTON PUMP INHIBITORS PRIOR TO DIAGNOSIS IS ASSOCIATED WITH INCREASED GASTRIC CANCER RISK. Digestive and Liver Disease, 2022, 54, S84.	0.4	0